COVID-19-associated thrombocytopenia: Difference between revisions

	WikiDoc Resources for COVID-19-associated thrombocytopenia
Articles
Most recent articles on COVID-19-associated thrombocytopenia Most cited articles on COVID-19-associated thrombocytopenia Review articles on COVID-19-associated thrombocytopenia Articles on COVID-19-associated thrombocytopenia in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on COVID-19-associated thrombocytopenia Images of COVID-19-associated thrombocytopenia Photos of COVID-19-associated thrombocytopenia Podcasts & MP3s on COVID-19-associated thrombocytopenia Videos on COVID-19-associated thrombocytopenia
Evidence Based Medicine
Cochrane Collaboration on COVID-19-associated thrombocytopenia Bandolier on COVID-19-associated thrombocytopenia TRIP on COVID-19-associated thrombocytopenia
Clinical Trials
Ongoing Trials on COVID-19-associated thrombocytopenia at Clinical Trials.gov Trial results on COVID-19-associated thrombocytopenia Clinical Trials on COVID-19-associated thrombocytopenia at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on COVID-19-associated thrombocytopenia NICE Guidance on COVID-19-associated thrombocytopenia NHS PRODIGY Guidance FDA on COVID-19-associated thrombocytopenia CDC on COVID-19-associated thrombocytopenia
Books
Books on COVID-19-associated thrombocytopenia
News
COVID-19-associated thrombocytopenia in the news Be alerted to news on COVID-19-associated thrombocytopenia News trends on COVID-19-associated thrombocytopenia
Commentary
Blogs on COVID-19-associated thrombocytopenia
Definitions
Definitions of COVID-19-associated thrombocytopenia
Patient Resources / Community
Patient resources on COVID-19-associated thrombocytopenia Discussion groups on COVID-19-associated thrombocytopenia Patient Handouts on COVID-19-associated thrombocytopenia Directions to Hospitals Treating COVID-19-associated thrombocytopenia Risk calculators and risk factors for COVID-19-associated thrombocytopenia
Healthcare Provider Resources
Symptoms of COVID-19-associated thrombocytopenia Causes & Risk Factors for COVID-19-associated thrombocytopenia Diagnostic studies for COVID-19-associated thrombocytopenia Treatment of COVID-19-associated thrombocytopenia
Continuing Medical Education (CME)
CME Programs on COVID-19-associated thrombocytopenia
International
COVID-19-associated thrombocytopenia en Espanol COVID-19-associated thrombocytopenia en Francais
Business
COVID-19-associated thrombocytopenia in the Marketplace Patents on COVID-19-associated thrombocytopenia
Experimental / Informatics
List of terms related to COVID-19-associated thrombocytopenia

← Older edit Newer edit →

VisualWikitext

Revision as of 14:51, 24 July 2020

For COVID-19 frequently asked inpatient questions, click here
For COVID-19 frequently asked outpatient questions, click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shakiba Hassanzadeh, MD [2]

Synonyms and keywords: Decrease in platelet count in COVID 19, effects of thrombocytopenia in COVID 19, thrombocytopenia complications of COVID 19

Overview

Coronavirus disease 2019 (COVID-19) is caused by a novel coronavirus called SARS-CoV-2, which caused a respiratory illness outbreak that was first detected in Wuhan, China. Thrombocytopenia in COVID-19 infection is more common is patients with severe infection and it has been reported that thrombocytopenia upon admission for COVID-19 infection is associated with poor outcome and mortality. Thrombocytopenia is defined by platelet count <150 x <math>10^9</math>/L on complete blood count (CBC). The pathogenesis of thrombocytopenia in COVID-19 infection is due to several factors such as: infection of bone marrow, cytokine storm caused by the COVID-19 infection, increase in autoantibodies and immune complexes, lung injury which causes megakaryocyte fragmentation, decrease in platelets may be due to the activation of platelets that result in platelet aggregation.

Historical Perspective

Coronavirus disease 2019 (COVID-19) is caused by a novel coronavirus called SARS-CoV-2, which caused a respiratory illness outbreak that was first detected in Wuhan, China.^[1]^[2]

On January 30, 2020, the outbreak was declared a Public Health Emergency of International Concern.
On March 12, 2020, the COVID-19 outbreak was declared a pandemic by the World Health Organization (WHO).

Classification

Thrombocytopenia in general is defined by platelet count <150 x <math>10^9</math>/L on complete blood count (CBC).^[3]
Classification of thrombocytopenia in general by platelet count is:^[4]
- Mild: between 70,000 and 150,000 x <math>10^9</math>/L
- Severe: less than 20,000 x <math>10^9</math>/L
In general:^[4]
- Most thrombocytopenic patients are asymptomatic if the platelet count is 50,000 x <math>10^9</math>/L or greater.
- Thrombocytopenic patients with platelet count between 30 and 50 x <math>10^9</math>/L rarely have purpura, but may have bleeding with trauma.
- Thrombocytopenic patients with platelet count between 10 and 30 x <math>10^3</math>/L may have bleeding with minor trauma.
- Thrombocytopenic patients with platelet count less than 10 x <math>10^3</math>/L have increased risk for spontaneous bleeding, petechiae, and bruising.
- In thrombocytopenic patients, spontaneous bleeding, which is an emergency, usually occurs in patients with platelet counts less than 5 x <math>10^3</math>/L .

Pathophysiology

The pathogenesis of thrombocytopenia in COVID-19 infection is due to several factors:^[5]^[6]^[7]^[8]^[9]^[10]

Decrease in primary platelet production due to infection of bone marrow cells by coronaviruses and inhibition of bone marrow growth, which lead to abnormal hematopoietic function.
Decrease in platelets may also be due to a cytokine storm caused by the COVID-19 infection which results in the destruction of bone marrow progenitor cells.
Increase in platelet destruction due to an increase in autoantibodies and immune complexes.
Decrease in circulating platelet due to lung injury which causes megakaryocyte fragmentation and decreases platelet production, because the lung is a reservoir for megakaryocyte and hematopoietic progenitor cells and has a role in platelet production.
In addition, a decrease in platelets may be due to the activation of platelets that result in platelet aggregation and formation of micro-thrombus which increase platelet consumption.

Summary of the mechanisms involved in thrombocytopenia in COVID-19 infection:^[5]

Causes

Coronavirus disease 2019 (COVID-19) is caused by a novel coronavirus called SARS-CoV-2 and is the cause of thrombocytopenia in COVID-19 infection.

Differentiating Thrombocytopenia from other Diseases

Coronavirus disease 2019 (COVID-19) may cause thrombocytopenia. The differential diagnosis to consider for thrombocytopenia in general include:^[11]
- Pseudothrombocytopenia
- Inherited thrombocytopenias (Bernard-Soulier syndrome, Wiskott-Aldrich syndrome, and thrombocytopenia with absent radii)
- Immune thrombocytopenic purpura (ITP) and drug-induced ITP (such as quinine, NSAIDs, glycoprotein IIb/IIIa inhibitors)
- Heparin-induced thrombocytopenia (HIT)
- Thrombotic thrombocytopenic purpura (TTP)/hemolytic uremic syndrome (HUS)
- Drug-induced TTP (such as mitomycin C, gemcitabine, oxaliplatin)
- Disseminated intravascular coagulation (DIC)
- Hematologic disorders (lymphoma, leukemia, myelodysplastic syndrome)
- Post-transfusion purpura
- Autoimmune-related thrombocytopenia (such as systemic lupus erythematosus (SLE), common variable immunodeficiency (CVID), antiphospholipid antibody syndrome,thyroid disease)
- Tumor infiltration of bone marrow
- Bone marrow failure (such as aplastic anemia, fanconi anemia, and diamond-Blackfan anemia)
- Liver disease
- Splenomegaly
- Infections (Epstein-Barr virus, cytomegalovirus, hepatitis C, HIV, parvovirus B19, H pylori)
- Drugs (antibiotics, alcohol, chemotherapy, radiation)
- Folate deficiency or vitamin B12 deficiency
- Mechanical destruction (such as cardiopulmonary bypass, intra-aortic balloon pump)

For detailed differential diagnosis of thrombocytopenia click here

Epidemiology and Demographics

Thrombocytopenia is seen in 36.2% of all patients with COVID-19 infection.^[12]
Thrombocytopeniais seen in 57.7% of patients with severe COVID-19 infection compared to 31.6 % of patients with non-severe infection.^[12]

Risk Factors

Thrombocytopenia in COVID-19 infection is more common is patients with severe infection compared to patients with non-severe infection.^[12]

Screening

It has been reported that thrombocytopenia upon admission for COVID-19 infection is associated with severe disease and mortality.^[13]
However, there is insufficient evidence to recommend routine screening and monitoring of thrombocytopenia for predicting disease progression in patients with COVID-19 infection and further studies are required.^[14]

Natural History, Complications, and Prognosis

Natural History

Thrombocytopenia is associated with an increased risk for severe COVID-19 infection (threefold).^[15]

Complications

Complications of thrombocytopenia in patients with severe COVID-19 infection may include:^[14]

Prognosis

It has been reported that thrombocytopenia upon admission for COVID-19 infection is independently and strongly associated with poor outcome and mortality.^[13]

Diagnosis

Diagnostic Study of Choice

The diagnostic study of choice for thrombocytopenia is complete blood count (CBC).

Thrombocytopenia in general is defined by platelet count <150 x <math>10^9</math>/L on CBC.^[3]
The median platelet count in COVID-19 patients with thrombocytopenia is 137,500 and 172,000 x <math>10^9</math>/L in severe and non-severe infection, respectively.^[12]

History and Symptoms

The median platelet count in COVID-19 patients with thrombocytopenia is 137,500 and 172,000 x <math>10^9</math>/L in severe and non-severe infection, respectively.^[12]
In general, in thrombocytopenic patients, most patients are asymptomatic if the platelet count is 50,000 x <math>10^9</math>/L or greater.^[4]

In general, in thrombocytopenic patients should be questioned about:^[3]^[4]
- Bruising or petechiae
- Bleeding (melena, epistaxis, menorrhagia, hematuria, prolonged bleeding after procedures, gingival bleeding and blood in sputum)
- Past medical history
- Family history
- Medications history
- Immunization history
- Changes in vision
- Rash
- Fever
- Recent travel
- Transfusion history

Physical Examination

The median platelet count in COVID-19 patients with thrombocytopenia is 137,500 and 172,000 x <math>10^9</math>/L in severe and non-severe infection, respectively.^[12]
In general, in thrombocytopenic patients, most patients are asymptomatic if the platelet count is 50,000 x <math>10^9</math>/L or greater.^[4]
The physical examination in patients with thrombocytopenia in general should include checking for:^[3]
- Bleeding (epistaxis, bloody sputum, gingival bleeding, menorrhagia, heavy bleeding after invasive procedures or childbirth)^[16]^[17]
- Unexplained bruising (petechiae, purpura, ecchymosis)
- Hepatosplenomegaly
- Abdominal tenderness
- Urinary tract (check for hematuria)^[18]
- Stool for occult blood (evaluation of gastrointestinal and rectal bleeding)
- Retinal hemorrhage on fundoscopic exam (evaluation of central nervous system bleeding)^[18]
- Neurologic examination (check for intracranial bleeding)^[18]
- Soft tissue or joint bleeding is not associated with thrombocytopenia and other coagulation disorders such as DIC should be checked.^[17]^[18]

Laboratory Findings

Complete blood count (CBC): Thrombocytopenia in general is defined by platelet count <150 x <math>10^9</math>/L on CBC.^[3]
- The median platelet count in COVID-19 patients with thrombocytopenia is 137,500 and 172,000 x <math>10^9</math>/L in severe and non-severe infection, respectively.^[12]

Peripheral blood smear: Peripheral blood smear may be helpful if there is suspicion of other disorders that cause thrombocytopenia. However, there is insufficient evidence recommending routine peripheral blood smear in COVID-19 patients.
Other laboratory testings (such as HIV, HCV testing, antibody testing, liver enzymes and liver function testing) are performed if there is suspicion of other disorders that cause thrombocytopenia.

Electrocardiogram

There are no ECG findings associated with COVID-19-associated-thrombocytopenia.

X-ray

There are no x-ray findings associated with COVID-19-associated-thrombocytopenia.

Echocardiography or Ultrasound

There are no echocardiography/ultrasound findings associated with COVID-19-associated-thrombocytopenia.

CT scan

There are no CT scan findings associated with COVID-19-associated-thrombocytopenia.

MRI

There are no MRI findings associated with COVID-19-associated-thrombocytopenia.

Other Imaging Findings

There are no other imaging findings associated with COVID-19-associated-thrombocytopenia.

Other Diagnostic Studies

There are no other diagnostic studies associated with COVID-19-associated-thrombocytopenia.
However, bone marrow biopsy may be helpful if there is suspicion of other disorders that cause thrombocytopenia, but there is insufficient evidence recommending routine bone marrow biopsy in COVID-19 patients.

Treatment

Medical Therapy

The treatment options for thrombocytopenia in COVID-19 infection include:^[19]

Rituximab
Thrombopoietin receptor agonists (eltrombopag, avatrombopag, romiplostim)
High-dose dexamethasone as an alternative to prednisone
Intravenous immunoglobulins (IVIG) (1 g/kg on 1 or 2 consecutive days or 0.4 g/kg per day for 5 days)
Intravenous anti-D (50–75 mg/kg once) (consider potential triggering of DIC or hemolysis)
Platelet growth factors in patients with bleeding, high risk for bleeding, unresponsive to prednisone (carefully evaluate due to the potential thrombotic events in corona-virus infection)
Platelet transfusion in refractory visceral or cerebral meningeal hemorrhage

Surgery

The mainstay of treatment for severe thrombocytopenia in COVID-19 infection is medical therapy.
Surgery has not been reported to be indicated in thrombocytopenia in COVID-19 infection.

Primary Prevention

There are no established measures for the primary prevention of thrombocytopenia in COVID-19 infection.

Secondary Prevention

There are no established measures for the secondary prevention of thrombocytopenia in COVID-19 infection. However, it may include avoidance of antiviral medications.

References

↑ https://www.cdc.gov/coronavirus/2019-ncov/about/index.html. Missing or empty |title= (help)
↑ Lu, Jian; Cui, Jie; Qian, Zhaohui; Wang, Yirong; Zhang, Hong; Duan, Yuange; Wu, Xinkai; Yao, Xinmin; Song, Yuhe; Li, Xiang; Wu, Changcheng; Tang, Xiaolu (2020). "On the origin and continuing evolution of SARS-CoV-2". National Science Review. doi:10.1093/nsr/nwaa036. ISSN 2095-5138.
↑ ^3.0 ^3.1 ^3.2 ^3.3 ^3.4 Greenberg EM (2017). "Thrombocytopenia: A Destruction of Platelets". J Infus Nurs. 40 (1): 41–50. doi:10.1097/NAN.0000000000000204. PMID 28030481.
↑ ^4.0 ^4.1 ^4.2 ^4.3 ^4.4 Gauer RL, Braun MM (2012). "Thrombocytopenia". Am Fam Physician. 85 (6): 612–22. PMID 22534274.
↑ ^5.0 ^5.1 Xu P, Zhou Q, Xu J (2020). "Mechanism of thrombocytopenia in COVID-19 patients". Ann Hematol. 99 (6): 1205–1208. doi:10.1007/s00277-020-04019-0. PMC 7156897 Check |pmc= value (help). PMID 32296910 Check |pmid= value (help).
↑ Yang M, Ng MH, Li CK (2005). "Thrombocytopenia in patients with severe acute respiratory syndrome (review)". Hematology. 10 (2): 101–5. doi:10.1080/10245330400026170. PMID 16019455.
↑ Yeager CL, Ashmun RA, Williams RK, Cardellichio CB, Shapiro LH, Look AT; et al. (1992). "Human aminopeptidase N is a receptor for human coronavirus 229E". Nature. 357 (6377): 420–2. doi:10.1038/357420a0. PMC 7095410 Check |pmc= value (help). PMID 1350662.
↑ Nardi M, Tomlinson S, Greco MA, Karpatkin S (2001). "Complement-independent, peroxide-induced antibody lysis of platelets in HIV-1-related immune thrombocytopenia". Cell. 106 (5): 551–61. doi:10.1016/s0092-8674(01)00477-9. PMID 11551503.
↑ Lefrançais E, Ortiz-Muñoz G, Caudrillier A, Mallavia B, Liu F, Sayah DM; et al. (2017). "The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors". Nature. 544 (7648): 105–109. doi:10.1038/nature21706. PMC 5663284. PMID 28329764.
↑ Liu X, Zhang R, He G (2020). "Hematological findings in coronavirus disease 2019: indications of progression of disease". Ann Hematol. doi:10.1007/s00277-020-04103-5. PMC 7266734 Check |pmc= value (help). PMID 32495027 Check |pmid= value (help).
↑ Lee EJ, Lee AI (2016). "Thrombocytopenia". Prim Care. 43 (4): 543–557. doi:10.1016/j.pop.2016.07.008. PMID 27866576.
↑ ^12.0 ^12.1 ^12.2 ^12.3 ^12.4 ^12.5 ^12.6 Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX; et al. (2020). "Clinical Characteristics of Coronavirus Disease 2019 in China". N Engl J Med. 382 (18): 1708–1720. doi:10.1056/NEJMoa2002032. PMC 7092819 Check |pmc= value (help). PMID 32109013 Check |pmid= value (help).
↑ ^13.0 ^13.1 Maquet J, Lafaurie M, Sommet A, Moulis G, Covid-Clinic-Toul investigators group. Alvarez M; et al. (2020). "Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID-19". Br J Haematol. doi:10.1111/bjh.16950. PMID 32557535 Check |pmid= value (help).
↑ ^14.0 ^14.1 Zhang Y, Zeng X, Jiao Y, Li Z, Liu Q, Ye J; et al. (2020). "Mechanisms involved in the development of thrombocytopenia in patients with COVID-19". Thromb Res. 193: 110–115. doi:10.1016/j.thromres.2020.06.008. PMC 7274097 Check |pmc= value (help). PMID 32535232 Check |pmid= value (help).
↑ Lippi G, Plebani M, Henry BM (2020). "Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis". Clin Chim Acta. 506: 145–148. doi:10.1016/j.cca.2020.03.022. PMC 7102663 Check |pmc= value (help). PMID 32178975 Check |pmid= value (help).
↑ Ghoshal K, Bhattacharyya M (2014). "Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis". ScientificWorldJournal. 2014: 781857. doi:10.1155/2014/781857. PMC 3960550. PMID 24729754.
↑ ^17.0 ^17.1 Stasi R (2012). "How to approach thrombocytopenia". Hematology Am Soc Hematol Educ Program. 2012: 191–7. doi:10.1182/asheducation-2012.1.191. PMID 23233580.
↑ ^18.0 ^18.1 ^18.2 ^18.3 Sekhon SS, Roy V (2006). "Thrombocytopenia in adults: A practical approach to evaluation and management". South Med J. 99 (5): 491–8, quiz 499-500, 533. doi:10.1097/01.smj.0000209275.75045.d4. PMID 16711312.
↑ Lorenzo-Villalba N, Zulfiqar AA, Auburtin M, Schuhmacher MH, Meyer A, Maouche Y; et al. (2020). "Thrombocytopenia in the Course of COVID-19 Infection". Eur J Case Rep Intern Med. 7 (6): 001702. doi:10.12890/2020_001702. PMC 7279909 Check |pmc= value (help). PMID 32523922 Check |pmid= value (help).

Template:WikiDoc Sources

[1] ttps://www.cdc.gov/coronavirus/2019-ncov/about/index.html. Missing or empty |title= (help)

[LuCui2020-2] Lu, Jian; Cui, Jie; Qian, Zhaohui; Wang, Yirong; Zhang, Hong; Duan, Yuange; Wu, Xinkai; Yao, Xinmin; Song, Yuhe; Li, Xiang; Wu, Changcheng; Tang, Xiaolu (2020). "On the origin and continuing evolution of SARS-CoV-2". National Science Review. doi:10.1093/nsr/nwaa036. ISSN 2095-5138.

[pmid28030481-3] 3.0 ^3.1 ^3.2 ^3.3 ^3.4 Greenberg EM (2017). "Thrombocytopenia: A Destruction of Platelets". J Infus Nurs. 40 (1): 41–50. doi:10.1097/NAN.0000000000000204. PMID 28030481.

[pmid22534274-4] 4.0 ^4.1 ^4.2 ^4.3 ^4.4 Gauer RL, Braun MM (2012). "Thrombocytopenia". Am Fam Physician. 85 (6): 612–22. PMID 22534274.

[pmid32296910-5] 5.0 ^5.1 Xu P, Zhou Q, Xu J (2020). "Mechanism of thrombocytopenia in COVID-19 patients". Ann Hematol. 99 (6): 1205–1208. doi:10.1007/s00277-020-04019-0. PMC 7156897 Check |pmc= value (help). PMID 32296910 Check |pmid= value (help).

[pmid16019455-6] Yang M, Ng MH, Li CK (2005). "Thrombocytopenia in patients with severe acute respiratory syndrome (review)". Hematology. 10 (2): 101–5. doi:10.1080/10245330400026170. PMID 16019455.

[pmid1350662-7] Yeager CL, Ashmun RA, Williams RK, Cardellichio CB, Shapiro LH, Look AT; et al. (1992). "Human aminopeptidase N is a receptor for human coronavirus 229E". Nature. 357 (6377): 420–2. doi:10.1038/357420a0. PMC 7095410 Check |pmc= value (help). PMID 1350662.

[pmid11551503-8] Nardi M, Tomlinson S, Greco MA, Karpatkin S (2001). "Complement-independent, peroxide-induced antibody lysis of platelets in HIV-1-related immune thrombocytopenia". Cell. 106 (5): 551–61. doi:10.1016/s0092-8674(01)00477-9. PMID 11551503.

[pmid28329764-9] Lefrançais E, Ortiz-Muñoz G, Caudrillier A, Mallavia B, Liu F, Sayah DM; et al. (2017). "The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors". Nature. 544 (7648): 105–109. doi:10.1038/nature21706. PMC 5663284. PMID 28329764.

[pmid32495027-10] Liu X, Zhang R, He G (2020). "Hematological findings in coronavirus disease 2019: indications of progression of disease". Ann Hematol. doi:10.1007/s00277-020-04103-5. PMC 7266734 Check |pmc= value (help). PMID 32495027 Check |pmid= value (help).

[pmid27866576-11] Lee EJ, Lee AI (2016). "Thrombocytopenia". Prim Care. 43 (4): 543–557. doi:10.1016/j.pop.2016.07.008. PMID 27866576.

[pmid32109013-12] 12.0 ^12.1 ^12.2 ^12.3 ^12.4 ^12.5 ^12.6 Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX; et al. (2020). "Clinical Characteristics of Coronavirus Disease 2019 in China". N Engl J Med. 382 (18): 1708–1720. doi:10.1056/NEJMoa2002032. PMC 7092819 Check |pmc= value (help). PMID 32109013 Check |pmid= value (help).

[pmid32557535-13] 13.0 ^13.1 Maquet J, Lafaurie M, Sommet A, Moulis G, Covid-Clinic-Toul investigators group. Alvarez M; et al. (2020). "Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID-19". Br J Haematol. doi:10.1111/bjh.16950. PMID 32557535 Check |pmid= value (help).

[pmid32535232-14] 14.0 ^14.1 Zhang Y, Zeng X, Jiao Y, Li Z, Liu Q, Ye J; et al. (2020). "Mechanisms involved in the development of thrombocytopenia in patients with COVID-19". Thromb Res. 193: 110–115. doi:10.1016/j.thromres.2020.06.008. PMC 7274097 Check |pmc= value (help). PMID 32535232 Check |pmid= value (help).

[pmid32178975-15] Lippi G, Plebani M, Henry BM (2020). "Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis". Clin Chim Acta. 506: 145–148. doi:10.1016/j.cca.2020.03.022. PMC 7102663 Check |pmc= value (help). PMID 32178975 Check |pmid= value (help).

[pmid24729754-16] Ghoshal K, Bhattacharyya M (2014). "Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis". ScientificWorldJournal. 2014: 781857. doi:10.1155/2014/781857. PMC 3960550. PMID 24729754.

[pmid23233580-17] 17.0 ^17.1 Stasi R (2012). "How to approach thrombocytopenia". Hematology Am Soc Hematol Educ Program. 2012: 191–7. doi:10.1182/asheducation-2012.1.191. PMID 23233580.

[pmid16711312-18] 18.0 ^18.1 ^18.2 ^18.3 Sekhon SS, Roy V (2006). "Thrombocytopenia in adults: A practical approach to evaluation and management". South Med J. 99 (5): 491–8, quiz 499-500, 533. doi:10.1097/01.smj.0000209275.75045.d4. PMID 16711312.

[pmid32523922-19] Lorenzo-Villalba N, Zulfiqar AA, Auburtin M, Schuhmacher MH, Meyer A, Maouche Y; et al. (2020). "Thrombocytopenia in the Course of COVID-19 Infection". Eur J Case Rep Intern Med. 7 (6): 001702. doi:10.12890/2020_001702. PMC 7279909 Check |pmc= value (help). PMID 32523922 Check |pmid= value (help).

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

@@ Line 13: / Line 13: @@
 ==Historical Perspective==
 * [[COVID-19|Coronavirus disease 2019 (COVID-19)]] is caused by a novel [[coronavirus]] called [[SARS-CoV-2]], which caused a respiratory illness [[outbreak]] that was first detected in Wuhan, China.<ref>{{Cite web|url=https://www.cdc.gov/coronavirus/2019-ncov/about/index.html|title=|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref><ref name="LuCui2020">{{cite journal|last1=Lu|first1=Jian|last2=Cui|first2=Jie|last3=Qian|first3=Zhaohui|last4=Wang|first4=Yirong|last5=Zhang|first5=Hong|last6=Duan|first6=Yuange|last7=Wu|first7=Xinkai|last8=Yao|first8=Xinmin|last9=Song|first9=Yuhe|last10=Li|first10=Xiang|last11=Wu|first11=Changcheng|last12=Tang|first12=Xiaolu|title=On the origin and continuing evolution of SARS-CoV-2|journal=National Science Review|year=2020|issn=2095-5138|doi=10.1093/nsr/nwaa036}}</ref>
@@ Line 20: / Line 19: @@
 ==Classification==
 *[[Thrombocytopenia]] in general is defined by [[platelet]] count <150 x <math>10^9</math>/L on [[complete blood count]] ([[Complete blood count|CBC]]).<ref name="pmid28030481" />
 *Classification of [[thrombocytopenia]] in general by [[platelet]] count is:<ref name="pmid22534274">{{cite journal| author=Gauer RL, Braun MM| title=Thrombocytopenia. | journal=Am Fam Physician | year= 2012 | volume= 85 | issue= 6 | pages= 612-22 | pmid=22534274 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22534274  }} </ref>
@@ Line 37: / Line 35: @@
 * Decrease in primary [[platelet]] production due to infection of [[bone marrow]] cells by [[Coronavirus|coronaviruses]] and inhibition of [[bone marrow]] growth, which lead to abnormal [[hematopoietic]] function.
 *Decrease in [[Platelet|platelets]] may also be due to a [[COVID-19-associated cytokine storm|cytokine storm]] caused by the [[COVID-19]] infection which results in the destruction of [[bone marrow]] [[Progenitor cell|progenitor cells]].
 * Increase in [[platelet]] destruction due to an increase in [[Autoantibody|autoantibodies]] and [[Immune complex|immune complexes]].
 * Decrease in circulating [[platelet]] due to [[lung]] injury which causes [[megakaryocyte]] fragmentation and decreases platelet production, because the lung is a reservoir for [[megakaryocyte]] and [[hematopoietic]] [[Progenitor cell|progenitor cells]] and has a role in [[platelet]] production.
 *In addition, a decrease in [[platelets]] may be due to the activation of [[Platelet|platelets]] that result in [[platelet]] [[aggregation]] and formation of micro-[[thrombus]] which increase [[platelet]] consumption.
 Summary of the mechanisms involved in [[thrombocytopenia]] in [[COVID-19]] infection:<ref name="pmid32296910" />[[ File:Covid 19 coagulation.jpg|center|800px]]
 ==Causes==
 * [[COVID-19|Coronavirus disease 2019 (COVID-19)]] is caused by a novel [[coronavirus]] called [[SARS-CoV-2]]  and is the cause of [[thrombocytopenia]] in [[COVID-19]] infection.
-==Differentiating Thrombocytopenia  from other Diseases==
+==Differentiating Thrombocytopenia from other Diseases==
 * [[COVID-19|Coronavirus disease 2019 (COVID-19)]]  may cause [[thrombocytopenia]]. The differential diagnosis to consider for [[thrombocytopenia]] in general include:<ref name="pmid27866576">{{cite journal| author=Lee EJ, Lee AI| title=Thrombocytopenia. | journal=Prim Care | year= 2016 | volume= 43 | issue= 4 | pages= 543-557 | pmid=27866576 | doi=10.1016/j.pop.2016.07.008 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27866576  }} </ref>
 **[[Pseudothrombocytopenia]]
@@ Line 73: / Line 68: @@
 ==Epidemiology and Demographics==
 *[[Thrombocytopenia]] is seen in 36.2% of all patients with COVID-19 infection.<ref name="pmid32109013" />
 *[[Thrombocytopenia]]<nowiki/>is seen in 57.7% of patients with severe [[COVID-19]] infection compared to 31.6 % of patients with non-severe infection.<ref name="pmid32109013">{{cite journal| author=Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX | display-authors=etal| title=Clinical Characteristics of Coronavirus Disease 2019 in China. | journal=N Engl J Med | year= 2020 | volume= 382 | issue= 18 | pages= 1708-1720 | pmid=32109013 | doi=10.1056/NEJMoa2002032 | pmc=7092819 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32109013  }} </ref>
 ==Risk Factors==
 * [[Thrombocytopenia]] in [[COVID-19]] infection is more common is patients with severe infection compared to patients with non-severe infection.<ref name="pmid32109013" />
 ==Screening==
 * It has been reported that [[thrombocytopenia]] upon admission for [[COVID-19]] infection is associated with severe disease and [[mortality]].<ref name="pmid32557535">{{cite journal| author=Maquet J, Lafaurie M, Sommet A, Moulis G, Covid-Clinic-Toul investigators group. Alvarez M | display-authors=etal| title=Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID-19. | journal=Br J Haematol | year= 2020 | volume=  | issue=  | pages=  | pmid=32557535 | doi=10.1111/bjh.16950 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32557535  }} </ref>
 * However, there is insufficient evidence to recommend routine [[Screening (medicine)|screening]] and monitoring of [[thrombocytopenia]] for predicting disease progression in patients with [[COVID-19]] infection and further studies are required.<ref name="pmid32535232">{{cite journal| author=Zhang Y, Zeng X, Jiao Y, Li Z, Liu Q, Ye J | display-authors=etal| title=Mechanisms involved in the development of thrombocytopenia in patients with COVID-19. | journal=Thromb Res | year= 2020 | volume= 193 | issue=  | pages= 110-115 | pmid=32535232 | doi=10.1016/j.thromres.2020.06.008 | pmc=7274097 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32535232  }} </ref>
@@ Line 89: / Line 81: @@
 === Natural History ===
 * [[Thrombocytopenia]] is associated with an increased risk for severe [[COVID-19]] infection (threefold).<ref name="pmid32178975">{{cite journal| author=Lippi G, Plebani M, Henry BM| title=Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. | journal=Clin Chim Acta | year= 2020 | volume= 506 | issue=  | pages= 145-148 | pmid=32178975 | doi=10.1016/j.cca.2020.03.022 | pmc=7102663 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32178975  }} </ref>
 === Complications ===
+*Complications of [[thrombocytopenia]] in patients with severe [[COVID-19]] infection may include:<ref name="pmid32535232" />
-* Complications of [[thrombocytopenia]] in patients with severe [[COVID-19]] infection may include:<ref name="pmid32535232" />
 **[[Disseminated intravascular coagulation|Disseminated intravascular coagulation (DIC)]]
-**[[Multiple organ dysfunction syndrome]]
+**[[Multiple organ dysfunction syndromes]]
 **Death
 === Prognosis ===
+*It has been reported that [[thrombocytopenia]] upon admission for [[COVID-19]] infection is independently and strongly associated with poor outcome and [[mortality]].<ref name="pmid32557535" />
-* It has been reported that [[thrombocytopenia]] upon admission for [[COVID-19]] infection is independently and strongly associated with poor outcome and [[mortality]].<ref name="pmid32557535" />
 ==Diagnosis==
 ===Diagnostic Study of Choice===
+*The [[diagnostic study of choice]] for [[thrombocytopenia]] is [[complete blood count]] ([[Complete blood count|CBC]]).
-* The [[diagnostic study of choice]] for [[thrombocytopenia]] is [[complete blood count]] ([[Complete blood count|CBC]]).
 *[[Thrombocytopenia]] in general is defined by [[platelet count]] <150 x <math>10^9</math>/L on [[Complete blood count|CBC]].<ref name="pmid28030481" />
@@ Line 112: / Line 100: @@
 ===History and Symptoms===
 *The median [[platelet]] count in [[COVID-19]] patients with [[thrombocytopenia]] is 137,500 and 172,000 x <math>10^9</math>/L in severe and non-severe infection, respectively.<ref name="pmid32109013" />
 * In general, in [[Thrombocytopenia|thrombocytopenic]] patients, most patients are asymptomatic if the platelet count is 50,000 x <math>10^9</math>/L or greater.<ref name="pmid22534274" />
@@ Line 128: / Line 115: @@
 ** Recent travel
 **[[Blood transfusion|Transfusion]] history
-*
-*
 ===Physical Examination===
 * The median [[platelet]] count in [[COVID-19]] patients with [[thrombocytopenia]] is 137,500 and 172,000 x <math>10^9</math>/L in severe and non-severe infection, respectively.<ref name="pmid32109013" />
 * In general, in [[Thrombocytopenia|thrombocytopenic]] patients, most patients are asymptomatic if the [[platelet]] count is 50,000 x <math>10^9</math>/L or greater.<ref name="pmid22534274" />
 * The [[physical examination]] in patients with [[thrombocytopenia]] in general should include checking for:<ref name="pmid28030481">{{cite journal| author=Greenberg EM| title=Thrombocytopenia: A Destruction of Platelets. | journal=J Infus Nurs | year= 2017 | volume= 40 | issue= 1 | pages= 41-50 | pmid=28030481 | doi=10.1097/NAN.0000000000000204 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28030481  }} </ref>
 ** Bleeding ([[epistaxis]], bloody [[sputum]], [[Gingiva|gingival]] [[bleeding]], [[menorrhagia]], heavy [[bleeding]] after invasive procedures or [[childbirth]])<ref name="pmid24729754">{{cite journal| author=Ghoshal K, Bhattacharyya M| title=Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis. | journal=ScientificWorldJournal | year= 2014 | volume= 2014 | issue=  | pages= 781857 | pmid=24729754 | doi=10.1155/2014/781857 | pmc=3960550 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24729754  }} </ref><ref name="pmid23233580">{{cite journal| author=Stasi R| title=How to approach thrombocytopenia. | journal=Hematology Am Soc Hematol Educ Program | year= 2012 | volume= 2012 | issue=  | pages= 191-7 | pmid=23233580 | doi=10.1182/asheducation-2012.1.191 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23233580  }} </ref>
@@ Line 155: / Line 137: @@
 *[[Blood film|Peripheral blood smear]]: [[Peripheral blood smear]] may be helpful if there is suspicion of other disorders that cause [[thrombocytopenia]]. However, there is insufficient evidence recommending routine [[peripheral blood smear]] in [[COVID-19]] patients.
 *Other [[laboratory]] testings (such as [[Human Immunodeficiency Virus (HIV)|HIV]], [[Hepatitis C|HCV]] testing, [[antibody]] testing, liver [[enzymes]] and [[Liver function tests|liver function testing]]) are performed if there is suspicion of other disorders that cause [[thrombocytopenia]].
-*
 ===Electrocardiogram===
 * There are no [[The electrocardiogram|ECG]] findings associated with [[COVID-19]]-associated-[[thrombocytopenia]].
 ===X-ray===
 * There are no [[X-rays|x-ray]] findings associated with [[COVID-19]]-associated-[[thrombocytopenia]].
 ===Echocardiography or Ultrasound===
 * There are no [[echocardiography]]/[[ultrasound]] findings associated with [[COVID-19]]-associated-[[thrombocytopenia]].
 ===CT scan===
 * There are no [[Computed tomography|CT]] scan findings associated with [[COVID-19]]-associated-[[thrombocytopenia]].
 ===MRI===
 * There are no [[Magnetic resonance imaging|MRI]] findings associated with [[COVID-19]]-associated-[[thrombocytopenia]].
 ===Other Imaging Findings===
 * There are no other imaging findings associated with [[COVID-19]]-associated-[[thrombocytopenia]].
@@ Line 191: / Line 165: @@
 The treatment options for [[thrombocytopenia]] in [[COVID-19]] infection include:<ref name="pmid32523922">{{cite journal| author=Lorenzo-Villalba N, Zulfiqar AA, Auburtin M, Schuhmacher MH, Meyer A, Maouche Y | display-authors=etal| title=Thrombocytopenia in the Course of COVID-19 Infection. | journal=Eur J Case Rep Intern Med | year= 2020 | volume= 7 | issue= 6 | pages= 001702 | pmid=32523922 | doi=10.12890/2020_001702 | pmc=7279909 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32523922  }} </ref>
-* [[Rituximab]]
+*[[Rituximab]]
 *[[Thrombopoietin]] receptor [[agonists]] ([[eltrombopag]], [[avatrombopag]], [[romiplostim]])
-* High-dose [[dexamethasone]] as an alternative to [[prednisone]]
+*High-dose [[dexamethasone]] as an alternative to [[prednisone]]
 *[[Intravenous]] [[immunoglobulins]] ([[IVIG]]) (1 g/kg on 1 or 2 consecutive days or 0.4 g/kg per day for 5 days)
 *[[Intravenous]] anti-D (50–75 mg/kg once) (consider potential triggering of [[Disseminated intravascular coagulation|DIC]] or [[hemolysis]])
@@ Line 200: / Line 174: @@
 ===Surgery===
 * The mainstay of treatment for severe [[thrombocytopenia]] in [[COVID-19]] infection is medical therapy.
 * Surgery has not been reported to be indicated in [[thrombocytopenia]] in [[COVID-19]] infection.
 ===Primary Prevention===
 * There are no established measures for the [[primary prevention]] of [[thrombocytopenia]] in [[COVID-19]] infection.
 ===Secondary Prevention===
 * There are no established measures for the [[secondary prevention]] of [[thrombocytopenia]] in [[COVID-19]] infection. However, it may include avoidance of [[antiviral]] [[Medication|medications]].
 ==References==
 {{reflist|2}}
+[[Category:Up-To-Date]]
 {{WikiDoc Help Menu}}
 {{WikiDoc Sources}}